A detailed history of State Street Corp transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,496,739 shares of AQST stock, worth $6.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,496,739
Previous 984,057 52.1%
Holding current value
$6.91 Million
Previous $2.56 Million 191.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.4 - $5.09 $1.23 Million - $2.61 Million
512,682 Added 52.1%
1,496,739 $7.45 Million
Q2 2024

Aug 14, 2024

BUY
$2.31 - $4.5 $1.85 Million - $3.61 Million
802,420 Added 441.77%
984,057 $2.56 Million
Q1 2024

May 15, 2024

BUY
$2.01 - $6.09 $60,500 - $183,309
30,100 Added 19.86%
181,637 $773,000
Q4 2023

Feb 14, 2024

BUY
$1.29 - $2.47 $18,318 - $35,074
14,200 Added 10.34%
151,537 $306,000
Q2 2023

Aug 14, 2023

BUY
$1.06 - $2.49 $43,778 - $102,837
41,300 Added 43.0%
137,337 $226,000
Q1 2022

May 16, 2022

BUY
$2.28 - $4.26 $20,428 - $38,169
8,960 Added 10.29%
96,037 $251,000
Q4 2021

Feb 14, 2022

BUY
$3.69 - $6.37 $63,468 - $109,564
17,200 Added 24.61%
87,077 $339,000
Q2 2021

Aug 16, 2021

SELL
$3.29 - $5.21 $834,890 - $1.32 Million
-253,766 Reduced 78.41%
69,877 $277,000
Q1 2021

May 17, 2021

BUY
$4.17 - $6.73 $36,495 - $58,900
8,752 Added 2.78%
323,643 $1.68 Million
Q4 2020

Feb 16, 2021

BUY
$4.65 - $7.79 $116,468 - $195,116
25,047 Added 8.64%
314,891 $1.69 Million
Q3 2020

Nov 10, 2020

BUY
$4.12 - $9.09 $4,589 - $10,126
1,114 Added 0.39%
289,844 $1.41 Million
Q2 2020

Aug 14, 2020

BUY
$1.84 - $6.44 $531,263 - $1.86 Million
288,730 New
288,730 $1.4 Million

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $246M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.